

Empowering Improved Outcomes in Breast Cancer Management in India.



3 MMC Credit Points Available.

Official

best of  SABCS®

6th & 7th January, 2024 | Trident, BKC, Mumbai

Official Partner

M | O | C Cancer Care & Research Centre

Save The Date

 SAN ANTONIO
BREAST CANCER
SYMPOSIUM®

Mays Cancer Center
UT Health MDAnderson
Cancer Center

AAGR
American Association
for Cancer Research

AN INITIATIVE OF
ENCORE
MEDICAL EDUCATION

SA BCS SAN ANTONIO
BREAST
CANCER
SYMPOSIUM®

Conference Brochure

The Official

best of  SABCS®

6th & 7th January, 2024 | Trident, BKC, Mumbai

Program Directors

Dr. Mangesh Mekha
MD, DM, DNB, ECOMO
Consultant Oncologist

Dr. Smit Sheth
MD, DM, ECOMO
Consultant Oncologist

Dr. Taha Sethjiwala
MD, DM
Consultant Oncologist

Scientific Committee Chair

Our Patrons

Dr. Mandar Nadkarni
MS, DNB
Sr. Surgical Oncologist, Breast Cancer

Dr. Senthil Rajappa
MD, DNB, DM
Sr. Medical Oncologist

Dr. Chirag Desai
MD, DM
Sr. Medical Oncologist

Official Partner

M | O | C Cancer Care & Research Centre



AN INITIATIVE OF



SAN ANTONIO
BREAST
CANCER
SYMPOSIUM®

Dear Colleagues,

Greetings from M | O | C Cancer Care & Research Centre!

M | O | C Cancer Care & Research Centre is proudly organizing a flagship academic conference, the **officially licensed Best of San Antonio Breast Cancer Symposium (SABCS)** on **6th & 7th January 2024**, at **Trident, BKC, Mumbai**. As you are aware that San Antonio Breast Cancer Symposium is a prestigious event of a high repute globally and M | O | C has been able to bring the path breaking and practice changing science to India through official means.

M | O | C has always been at the forefront of conducting high quality academic programs in various site-specific oncology care and "Official Best of SABCS" is another attempt to gather all the esteemed oncologists and allied specialities to raise the collective wisdom in breast oncology.

M | O | C Cancer Care & Research Centre intends to bring all the leading faculty engaged in dedicated breast cancer care from across India to come on a common platform to discuss the original research content from SABCS 2023 and its relevance to Indian context through case based interactive discussions during this conference. We expect over 150-200 faculty and 300 delegates to attend a 2-day academic feast on breast cancer. The conference is expected to cover MDT aspects of following topics in breast cancer management.

- Hormone Positive Breast Cancer
- HER 2 Mutated Breast Cancer
- Triple Negative Breast Cancers
- Precision Breast Oncology
- Pregnancy & Breast Cancers
- Lifestyle & Breast Cancers

Thank you.

Dr. Mangesh Mekha

MD, DM, DNB, ECOMO
Consultant Oncologist

Dr. Smit Sheth

MD, DM, ECOMO
Consultant Oncologist

Dr. Taha Sethjiwala

MD, DM
Consultant Oncologist

Official Partner

M | O | C Cancer Care & Research Centre



AN INITIATIVE OF



Scientific Committee

<p>Dr. Nita Nair DNB (Gen. Surg.), Breast Surgeon MRCS(Ed), MCh (Surg. Oncology) Apollo, Mumbai</p>	<p>Dr. Jay R. Anam DNB, MCh. (Surgical Oncology) Breast Cancer, Oncoplasty & LYMPHA Surgeon. Specialty Surgical Oncology (SSO) Hospital, Mumbai</p>	<p>Dr. Niharika Garach MS, MCh Surgical Oncologist Specialty Surgical Oncology (SSO) Hospital, Mumbai</p>
<p>Dr. Akshay Shivchhand MD, DM, DNB, ECMO Medical Oncologist M O C Kolhapur</p>	<p>Dr. Ashish Joshi MD, DM Medical Oncologist M O C Vile Parle & Borivali</p>	<p>Dr. C. V. Pethe MD, DM Medical Oncologist M O C Nashik</p>
<p>Dr. Devendra Pal MD, DNB, ECMO Medical Oncologist M O C Panvel</p>	<p>Dr. Krushna Chaudhari DNB, DNB, ECMO Medical Oncologist M O C Indore</p>	<p>Dr. Kshitij Joshi MD, DM, DNB, ECMO Medical Oncologist M O C Vile parle</p>
<p>Dr. Kunal Jobanputra MD, DM, ECMO Medical Oncologist M O C Mahim</p>	<p>Dr. Makarand Randive MD, DNB, ECMO Medical Oncologist M O C Nagpur</p>	<p>Dr. Nitin Bayas DNB, DNB Medical Oncologist M O C Borivali</p>
<p>Dr. Prakash Devde MD, DM Medical Oncologist M O C Aurangabad</p>	<p>Dr. Pradip Kendre DNB, DM Medical Oncologist M O C Thane</p>	<p>Dr. Pritam Kalaskar MD, DM Medical Oncologist M O C Thane</p>
<p>Dr. Pravin Khandare MD, DM Medical Oncologist M O C Thane</p>	<p>Dr. Ravikumar Wategaonkar MD, DM Medical Oncologist M O C Pimpri-Chinchwad</p>	<p>Dr. Ritu Dave DNB, DNB, ECMO Medical Oncologist M O C Pune</p>
<p>Dr. S. M. Carthikeyan MD, DNB, DM, MRCP, ECMO Medical Oncologist M O C Ghatkopar</p>	<p>Dr. Seema Jagiasi DNB, DNB Medical Oncologist M O C Kemps Corner</p>	<p>Dr. Sonal Dhande DNB, DNB Medical Oncologist M O C Nashik</p>
<p>Dr. Udip Maheshwari MD, DNB, ECMO Medical Oncologist M O C Ghatkopar</p>		<p>Dr. Vashishth Maniar MD, DM, ECMO Medical Oncologist M O C Ghatkopar & Kemps</p>

Official Partner

M | O | C Cancer Care & Research Centre



Esteemed Faculty

Dr. Abhishek Shankar
 Dr. Adwaita Gore
 Dr. Ajay Jadhav
 Dr. Ajay Kolse
 Dr. Akshay Shivchhand
 Dr. Alpesh Kikani
 Dr. Amish Dalal
 Dr. Ankit Batra
 Dr. Ankit Patel
 Dr. Anupama Mane
 Dr. Anupkumar Rawool
 Dr. Arun Kumar Goel
 Dr. Asha Reddy
 Dr. Ashish Bhanage
 Dr. Ashish Joshi
 Dr. Ashish Singh
 Dr. Ashutosh Tondare
 Dr. Ashwin Rajbhoj
 Dr. B. K. Smruti
 Dr. Bhavesh Parekh
 Dr. Bhavin Visariya
 Dr. Bhavisha Ghugare
 Dr. Bhavna Parikh
 Dr. Chandrashekhar Pethe
 Dr. Chetan Deshmukh
 Dr. Chintamani
 Dr. Chintan Shah
 Dr. Chirag Desai
 Dr. Chirantan Bose
 Dr. D G Vijay
 Dr. Debanshu Bhaduri
 Dr. Deepanjali Adulkar
 Dr. Devendra Pal
 Dr. Garima Daga
 Dr. Garvit Chitkara
 Dr. Honey Parekh
 Dr. Jay Anam

Dr. Jayesh Gori
 Dr. Jyoti Bajpai
 Dr. Kamlesh Bokil
 Dr. Karishma Kirti
 Dr. Kaushal Patel
 Dr. Kaustubh Kulkarni
 Dr. Kiran Kattimani
 Dr. Kiran Kumar DVS
 Dr. Kiran Rajole
 Dr. Krupa Shankar
 Dr. Krushna Chaudhari
 Dr. Kshitij Joshi
 Dr. Kunal Jobanputra
 Dr. Lovin Wilson
 Dr. Makarand Bhole
 Dr. Makarand Randive
 Dr. Mandar Nadkarni
 Dr. Mangesh Mekha
 Dr. Mangesh Patil
 Dr. Manish Sharma
 Dr. Manisha Jagtap
 Dr. Mansi Gore
 Dr. Mansi Khanderia
 Dr. Mubarakunnisa Tonse
 Dr. Muzammil Shaikh
 Dr. Nagesh Sirsat
 Dr. Nagraj Huilgol
 Dr. Namita Pandey
 Dr. Navin Kasliwal
 Dr. Neemesh Lodh
 Dr. Neerja Gupta
 Dr. Nita Nair
 Dr. Neha Choudhary
 Dr. Niharika Garach
 Dr. Nikhil Dharmadhikari
 Dr. Nikhilesh Borkar
 Dr. Nilesh Lokeshwar

Dr. Nilima Bhamre
 Dr. Nitin Bayas
 Dr. Nitin Tathe
 Dr. Pankaj Goyal
 Dr. Parveen Jain
 Dr. Piyush Shukla
 Dr. Prachi Thakar
 Dr. Prakash Devde
 Dr. Pranav Chadha
 Dr. Pranjali Gadgil
 Dr. Pritam Kalaskar
 Dr. Pritam Kataria
 Dr. Priyanka Patel
 Dr. Purvi Thakkar
 Dr. Rahul Jaiswal
 Dr. Rahul Kulkarni
 Dr. Rajat Bajaj
 Dr. Rajesh Saoji
 Dr. Rajiv Sarin
 Dr. Rashmi Gudur
 Dr. Ravi Wategaonkar
 Dr. Ravindra Mahajan
 Dr. Reshma Puranik
 Dr. Revathy Krishnamurthy
 Dr. Ridhima Bindlish
 Dr. Ritu Dave
 Dr. Sambasivaiah
 Dr. Sameeksha Dubey
 Dr. Sandeep De
 Dr. Sandeep Goyle
 Dr. Sandip Sonawane
 Dr. Sanjay Dudhat
 Dr. Sanjit Agrawal
 Dr. Sanjog Jaiswal
 Dr. Sanket Shah
 Dr. Saphalata Baghmar
 Dr. Seema Jagiasi

Dr. Senthil Rajappa
 Dr. Shalaka Joshi
 Dr. Sharad Desai
 Dr. Sharada Mailankody
 Dr. Shilpy Dolas
 Dr. Shruti Kate
 Dr. Smit Sheth
 Dr. Sonal Dhande
 Dr. Sudeep Gupta
 Dr. Suhas Aagre
 Dr. Suman Bijlani
 Dr. Sumit Shah
 Dr. Sushant Ikhari
 Dr. T Raja
 Dr. Taha Sethjiwala
 Dr. Tejinder Singh
 Dr. Tushar Patil
 Dr. Udipt Maheshwari
 Dr. Vaishali Zamre
 Dr. Vani Parmar
 Dr. Vashishth Maniar
 Dr. Vijay Guru
 Dr. Vinayak Shenage
 Dr. Vinod Gore
 Dr. Viraj Borgaonkar
 Dr. Vishwajeeth Pai
 Dr. Vivek Agarwala
 Dr. Yogen Chheda
 Dr. Yogesh Anap

Official Partner

Conference Attractions



**RENOWNED
MULTIDISCIPLINARY
EXPERTS**



**GLOBAL
SCIENTIFIC
UPDATES**



**PRACTICE
DISRUPTING
RESEARCH**



**INDUSTRY
DRIVEN
INNOVATIONS**

Official Partner

M | O | C Cancer Care & Research Centre



AN INITIATIVE OF



SAN ANTONIO
BREAST
CANCER
SYMPOSIUM[®]

Index

Day 1, Saturday 06th January, 2024

Session 1	: 08:45–09:50 : Pregnancy & Breast Cancer	01
Session 2	: 09:50–10:45 : Radiotherapy Update in Breast Cancer	03
Session 3	: 11:00–11:55 : Hormone Positive Early Breast Cancer.....	04
Session 4	: 13:45–14:35 : Hormone Positive Metastatic Breast Cancer	06
Session 5	: 14:35–15:25 : Antibody Drug Conjugate in Breast Cancer	08
Session 6	: 15:35–16:35 : Axillary Resection in Breast Cancer	09
Session 7	: 16:35–17:35 : Triple Negative Breast Cancer	11

Day 2, Sunday 07th January, 2024

Session 8	: 09:30–10:25 : Surgical Margins in Breast Cancer.....	15
Session 9	: 10:25–11:15 : Precision Oncology in Breast Cancer	16
Session 10	: 11:30–12:20 : HER 2 +ve Early Breast Cancer	17
Session 11	: 12:20–13:20 : HER 2 +ve Metastatic Breast Cancer	19

Scientific Program

Day 1, Saturday 06th January, 2024

08:40-08:45

Welcome Address

Session 1 : 08:45-09:50 : Pregnancy & Breast Cancer

Session Coordinators : Dr. Kshitij Joshi & Dr. Nitin Bayas

Chairperson : Dr. Mandar Nadkarni, Dr. Sandip Sonawane

08:45-08:50

Topic 1 :

PS10-01 Hormonal contraception and breast cancer risk for carriers of germline pathogenic variants in BRCA1 and BRCA2

Speaker : Dr. Priyanka Patel

08:50-08:55

Topic 2

GS02-11 Fertility preservation and assisted reproductive technologies (ART) in breast cancer (BC) patients (pts) interrupting endocrine therapy (ET) to attempt pregnancy.

Speaker : Dr. Seema Jagiasi

08:55-09:00

Topic 3

GS02-13 Pregnancy after breast cancer in young women with germline BRCA pathogenic variants: results from an international cohort study

Speaker : Dr. Ritu Dave

09:00-09:05

Topic 4

PS13-01 Worse prognosis for breast cancer in the second and third trimesters and shortly postpartum: An update of the Dutch pregnancy-associated breast cancer cohort

Speaker : Dr. Carthikeyan SM

Scientific Program

Day 1, Saturday 06th January, 2024

09:05–09:10

Topic 5

PS13-02 Clinical outcome and patients' characteristics of breast cancer diagnosed during pregnancy: A retrospective single institutional study

Speaker : Dr. Bhavisha Ghugare

09:10–09:15

Topic 6

PS13-03 Safety of taxane chemotherapy for the treatment of breast cancer during pregnancy: an international cohort study

Speaker : Dr. Mansi Khanderia

09:15–09:20

Topic 7

A randomized, open-label phase III trial evaluating low-dose vs standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy - induced nausea and vomiting in solid tumors (OLAnzaPiNE)

Speaker : Dr. Jyoti Bajpai

09:20–09:45

Case Based Panel Discussion

Moderator : Dr. Jyoti Bajpai

Panelist : Dr. Nilima Bhamare, Dr. Kshitij Joshi, Dr. Kaustubh Kulkarni, Dr. Kiran Rajole, Dr. Niharika Garach, Dr. Mansi Gore, Dr. Urvashi Jain, Dr. Seema Jagiasi, Dr. Prachi Thakar

09:45–09:50

Concluding Remarks : Dr. Mandar Nadkarni, Dr. Sandip Sonawane

Scientific Program

Day 1, Saturday 06th January, 2024

Session 2 : 09:50–10:45 : Radiotherapy Update in Breast Cancer

Session Coordinators : Dr. Pritam Kalaskar & Dr. Udip Maheshwari

Chairperson : Dr. Nagraj H, Dr. Manish Chandra

09:50–09:55

Topic 1

GS02–08 Five-year outcomes of the IDEA trial of endocrine therapy without radiotherapy after breast-conserving surgery for postmenopausal patients age 50–69 with genomically-selected favorable Stage I breast cancer

Speaker : Dr. Ashish Bhange

09:55–10:00

Topic 2

GS02–07 Loco-regional irradiation in patients with biopsy-proven axillary node involvement at presentation who become pathologically node-negative after neoadjuvant chemotherapy: primary outcomes of NRG Oncology/NSABP B-51/RTOG 1304

Speaker : Dr. Ajay Kolse

10:00–10:05

Topic 3

PS04–03 Survival benefit of regional nodal irradiation in clinically node-positive breast cancer following neoadjuvant chemotherapy and breast-conserving surgery

Speaker : Dr. Deepanjali Adulkar

10:05–10:10

Topic 4

PS02–03 Is de-escalation of treatment by omission of radiotherapy associated with fear of cancer recurrence and health-related quality of life in women with early breast cancer?

Speaker : Dr. Revathy Krishnamurthy

Scientific Program

Day 1, Saturday 06th January, 2024

10:10-10:15

Topic 5

Feasibility of monitoring Global Breast Cancer Initiative Framework key performance indicators in 21 Asian National Cancer Centers Alliance member countries

Speaker : Dr. Abhishek Shankar

10:15-10:40

Case Based Panel Discussion

Moderator : Dr. Rajiv Sarin

Panelist : Dr. Abhishek Shankar, Dr. Pranav Chadha, Dr. Yogesh Anap, Dr. Piyush Shukla, Dr. Ravi Mahajan, Dr. Ajay Kolse, Dr. Mangesh Patil

10:40-10:45

Concluding Remarks : Dr. Nagraj H, Dr. Manish Chandra

10:45-11:00 : Refreshments

Session 3 : 11:00-11:55 : Hormone Positive Early Breast Cancer

Session Coordinators : Dr. Akshay Shivchhand & Dr. Ritu Dave

Chairpersons : Dr. Sudeep Gupta, Dr. DG Vijay

11:00-11:05

Topic 1

Biomarker results in high-risk estrogen receptor positive, human epidermal growth factor receptor 2 negative primary breast cancer following neoadjuvant chemotherapy ± nivolumab: An exploratory analysis of CheckMate 7FL

Speaker : Dr. Mubarakunnisa Tonse

Scientific Program

Day 1, Saturday 06th January, 2024

11:05-11:10

Topic 2

Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2- breast cancer: KEYNOTE-756

Speaker : Dr. Rahul Kulkarni

11:10-11:15

Topic 3

GS03-03 Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2- early breast cancer: final invasive disease-free survival (iDFS) analysis from the NATALEE trial

Speaker : Dr. Kunal Jobanputra

11:15-11:20

Topic 4

LBO1-05 Impact of age and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Results from the multicenter ADAPTcycle trial

Speaker : Dr. Ankit Batra

11:20-11:25

Topic 5

Accuracy and safety of fibroblast activation protein inhibitor (FAPI) PET/CT in diagnosis of axillary lymph node metastasis in early breast cancer patients: a prospective cohort study (PFB-01&02 study)

Speaker : Dr. Reshma Puranik

Scientific Program

Day 1, Saturday 06th January, 2024

11:25–11:50

Case Based Panel Discussion

Moderator : Dr. Senthil Rajappa

Panelist : Dr. Muzammil Shaikh, Dr. Udip Maheshwari, Dr. Vashishth Maniar, Dr. Viraj Borgaonkar, Dr. Sanjog Jaiswal, Dr. Nagraj H

11:50–11:55

Concluding Remarks : Dr. Sudeep Gupta, Dr. DG Vijay

11:55–12:05 : Conference Inauguration

12:05–12:35

Keynote session

Breast cancer management: clinical decision to molecular decision – where have we reached and where are we going.

Speaker : Dr. T. Raja

12:35–12:55

Industry Session 1 : MSD Symposium : Role of immunotherapy and Its sequencing strategy, advanced triple negative breast cancer – Dr. Amit Bhat

12:55–13:15

Industry Session 2 : MSD Symposium : Redefining treatment outcomes with immunotherapy – early triple negative breast cancer (TNBC) – Dr. Vijay Patil

13:15–13:45 : Lunch

Session 4 : 13:45–14:35 : Hormone Positive Metastatic Breast Cancer

Session Coordinators : Dr. Udip Maheshwari & Dr. Seema Jagiasi

Chairperson : Dr. Chintamani, Dr. Suman Bijlani

Scientific Program

Day 1, Saturday 06th January, 2024

13:45–13:50

Topic 1

GS02-01 Randomised phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with inoperable or metastatic hormone receptor-positive, HER2- breast cancer: efficacy, safety and biomarker results from TROPION-Breast01

Speaker : Dr. Vishwajeeth Pai

13:50–13:55

Topic 2

PS17-03 Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant HR positive/HER2-negative advanced breast cancer: exploratory analysis of PFS by AKT pathway gene from the Phase 3 CAPitello-291 trial

Speaker : Dr. Sushant Ikhar

13:55–14:00

Topic 3

Efficacy, safety, and quality of life with ribociclib + endocrine therapy in elderly patients with HR+/HER2- advanced breast cancer across the MONALEESA-2, -3, and -7 trials

Speaker : Dr. Pritam Kataria

14:00–14:05

Topic 4

RF01-03 PARSIFAL-LONG: Extended follow-up of hormone receptor-positive /HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs. letrozole and palbociclib in the PARSIFAL study

Speaker : Dr. Vijay Guru

Scientific Program

Day 1, Saturday 06th January, 2024

14:05–14:30

Case Based Panel Discussion

Moderator : Dr. Ashish Joshi

Panelist : Dr. Nagesh Sirsat, Dr. Rahul Jaiswal, Dr. Bhavesh Parekh,
Dr. Sambasiviah, Dr. Nilesh Lokeshwar, Dr. Kiran Kattimani, Dr. Tushar Patil

14:30–14:35

Concluding Remarks : Dr. Chintamani, Dr. Suman Bijlani

Session 5 : 14:35–15:25 : Antibody Drug Conjugate in Breast Cancer

Session Coordinators : Dr. Sonal Dhande & Dr. Makarand Randive

Chairperson : Dr. C. V. Pethe, Dr. Manisha Jagtap

14:35–14:40

Topic 1

PS08–03 Sequencing antibody–drug conjugate after antibody–drug conjugate in metastatic breast cancer (A3 study): Multi–institution experience and biomarker analysis

Speaker : Dr. Saphalta Baghmar

14:40–14:45

Topic 2

PS08–02 Efficacy of Sacituzumab–Govitecan (SG) post Trastuzumab–deruxtecan (T–DXd) and vice versa for HER2 low advanced or metastatic breast cancer (MBC): a French multicentre retrospective study

Speaker : Dr. Sanket Shah

Scientific Program

Day 1, Saturday 06th January, 2024

14:45–14:50

Topic 3 :

PS08–04 Multicenter retrospective cohort study of the sequential use of the antibody–drug conjugates (ADCs) trastuzumab deruxtecan (T–DXd) and sacituzumab govitecan (SG) in patients with HER2–low metastatic breast cancer (MBC)

Speaker : Dr. Chintan Shah

14:50–14:55

Topic 4

PS08–01 Antibody–Drug Conjugates (ADCs) in breast cancer: Real world analysis of outcomes

Speaker : Dr. Ashwin Rajbhoj

14:55–15:20

Case Based Panel Discussion

Moderator : Dr. Chirag Desai

Panelist : Dr. Pritam Kalaskar, Dr. Parveen Jain, Dr. Tejinder Singh, Dr. Devendra Pal, Dr. Adwaita Gore, Dr. Ashish Singh, Dr. Bhavna Parikh

15:20–15:25

Concluding Remarks : Dr. C. V. Pethe, Dr. Manisha Jagtap

15:25–15:35 : Refreshments

Session 6 : 15:35–16:35 : Axillary Resection in Breast Cancer

Session Coordinators : Dr. Jay Anam & Dr. Smit Sheth

Chairperson : Dr. Sharad Desai, Dr. Vani Parmar

Scientific Program

Day 1, Saturday 06th January, 2024

15:35–15:40

Topic 1

Demystifying the axilla: Challenging scenarios in upfront surgery setting and after neoadjuvant chemotherapy

Speaker : Dr. Neemesh Lodh

15:40–15:45

Topic 2

GS02–05 Overview of axillary treatment in early breast cancer: patient-level meta-analysis of long-term outcomes among 20,273 women in 29 randomised trials

Speaker : Dr. Pranjali Gadgil

15:45–15:50

Topic 3 :

GS02–06 Recurrence-free survival following sentinel node-positive breast cancer without completion axillary lymph node dissection – first results from the international randomized SENOMAC trial

Speaker : Dr. Niharika Garach

15:50–15:55

Topic 4

PS01–02 Long-term outcomes of sentinel lymph node biopsy following neoadjuvant chemotherapy for initially node-positive breast cancer: A systematic review and meta-analysis

Speaker : Dr. Garima Daga

Scientific Program

Day 1, Saturday 06th January, 2024

15:55–16:00

Topic 5

PS01-03 What to expect from the No axillary surgical treatment for lymph node-negative patients after ultra-sonography [NAUTILUS] trial (KBCSG-21): Clinicopathologic characteristics and axillary lymph node status of enrolled patients

Speaker : Dr. Ridhima Bindlish

16:00–16:05

Topic 6

PS01-04 To dissect or not to dissect? The surgeon's perspective on the prediction of ≥ 4 axillary lymph node metastasis in cN0 T1-2 breast cancer: A comparative analysis of the per-protocol population of the SINODAR-ONE clinical trial.

Speaker : Dr. Shalaka Joshi

16:05–16:30

Case Based Panel Discussion

Moderator : Dr. Mandar Nadkarni

Panelist : Dr. Anupama Mane, Dr. Jay Anam, Dr. Kamlesh Bokil, Dr. Ajay Jadhav, Dr. Amish Dalal, Dr. Asha Reddy, Dr. Nikhilesh Borkar, Dr. Ashutosh Tondare, Dr. Sanjit Agarwal

16:30–16:35

Concluding Remarks : Dr. Sharad Desai, Dr. Vani Parmar

Session 7 : 16:35–17:35 : Triple Negative Breast Cancer

Session Coordinators : Dr. Taha Sethjiwala & Dr. Krushna Chaudhari

Chairperson : Dr. Vinayak Shenage, Dr. Kamlesh Bokil

Scientific Program

Day 1, Saturday 06th January, 2024

16:35–16:40

Topic 1

PS16-01 Comparison of an Atezolizumab monotherapy window followed by Atezolizumab and chemotherapy vs. Atezolizumab and chemotherapy alone in triple negative breast cancer (TNBC) – final analysis of the neoadjuvant neoMono trial

Speaker : Dr. Akshay Shivchhand

16:40–16:45

Topic 2

PS16-06 Tumor-infiltrating lymphocytes and pathologic response to neoadjuvant chemotherapy with the addition of platinum and pembrolizumab in TNBC: A single-center real-world study

Speaker : Dr. Arnav Tongaonkar

16:45–16:50

Topic 3

PS16-07 Tumor infiltrating lymphocyte stratification refines AJCC TNM staging based outcomes of early-stage triple negative breast cancer treated with neoadjuvant anthracycline-free, docetaxel and carboplatin chemotherapy

Speaker : Dr. Shruti Kate

16:50–16:55

Topic 4

PS16-02 Efficacy and safety of first-line atezolizumab + bevacizumab + paclitaxel in patients with advanced triple-negative breast cancer: the ATRACTIB phase 2 trial

Speaker : Dr. Kiran Kumar DVS

Scientific Program

Day 1, Saturday 06th January, 2024

16:55–17:00

Topic 5

Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage Triple-Negative Breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study

Speaker : Dr. Alpesh Kikani

17:00–17:05

Topic 6

LBO1-03 Randomized Phase II Study of Neoadjuvant Nivolumab (N) 2 week lead-in followed by 12 weeks of concurrent N+carboplatin plus paclitaxel (CbP) vs concurrent N+CbP in Triple Negative Breast Cancer

Speaker : Dr. Makarand Randive

17:05–17:30

Case Based Panel Discussion

Moderator : Dr. Mangesh Mekha

Panelist : Dr. Vinod Gore, Dr. Yogen Chheda, Dr. Ravi Wategaonkar, Dr. Sandip Goyle, Dr. Vashishth Maniar, Dr. Sandip De, Dr. Adwaita Gore, Dr. Nikhil Dharmadhikari

17:30–17:35

Concluding Remarks : Dr. Vinayak Shenage, Dr. Kamlesh Bokil

17:35–18:05

Industry Session 3 : Astra Symposium : Evolving trends in the management of HER2 positive mBC – Dr. Vashishth Maniar

18:05–18:35

Industry Session 4 : Roche Symposium – Dr. Sandeep Goyle

Moderator : Dr. Ashish Joshi

Panelist : Dr. Ashwin Rajbhoj, Dr. Sushant Ikhari, Dr. Shruti Kate, Dr. Garvit Chitkara, Dr. Anbarsan Sekar, Dr. Ravikumar Wategaonkar

Scientific Program

Day 1, Saturday 06th January, 2024

18:35-19:05

Industry Session 5 : Novartis Symposium : Dilemma of Choosing a CDK4/6i in mBC 1L setting.. reality or myth?

Moderator : Dr. Tejinder Singh

Panelist : Dr. Sandeep Goyle, Dr. Anarbasan Sekar, Dr. Pankaj Goyal, Dr. Chirag Desai

19:05-19:25

Industry Session 6 : Zydus Symposium

19:25-19:45

Industry Session 7 : Pfizer Symposium : Management strategies for HR+ /HER- mBC patients – Dr. Pankaj Goyal

19:45-20:00

Industry Session 8 : Lilly Symposium : Monarch E- 5 Year Update – Dr. Sandeep Goyle

20:30 Onwards : Conference Dinner

Scientific Program

Day 2, Sunday 07th January, 2024

09:00–09:30

Industry Session 9 : Astra : HER2 low as an emerging entity – Dr. Chirag Desai

Session 8 : 09:30–10:25 : Surgical Margins in Breast Cancer

Session Coordinators : Dr. Jay Anam & Dr. Smit Sheth

Chairpersons : Dr. Debanshu Bhaduri, Dr. Vani Parmar

09:30–09:35

Topic 1

Surgical management of Stage I, TNBC and HER2 + breast cancer

Speaker : Dr. Neha Choudhary

09:35–09:40

Topic 2

PS01-08 Management of ipsilateral breast tumor recurrence following breast conservation surgery for ductal carcinoma in situ – a data-free zone

Speaker : Dr. Namita Pandey

09:40–09:45

Topic 3

PS01-10 Surgical margins in breast conserving surgery (BCS) for ductal carcinoma in-situ (DCIS) and clinical outcomes: significant associations with increased recurrence and overall survival.

Speaker : Dr. Urvashi Jain

09:45–09:50

Topic 4

GS02-04 Surgical treatment of women with breast cancer and a BRCA1 mutation: an international analysis of the impact of bilateral mastectomy on survival

Speaker : Dr. Purvi Thakker

Scientific Program

Day 2, Sunday 07th January, 2024

09:50-09:55

Topic 5

PS01-06 The relationship between margin status of <2mm and local recurrence in DCIS patients

Speaker : Dr. Karishma Kirti

09:55-10:20

Case Based Panel Discussion

Moderator : Dr. Nita Nair

Panelist : Dr. Makarand Bhole, Dr. Sumit Shah, Dr. Shilpy Dolas, Dr. Nitin Tathe, Dr. Navin Kasliwal, Dr. Garvit Chitkara, Dr. Vaishali Zamre, Dr. Arun Goel, Dr. Urvashi Jain

10:20-10:25

Concluding Remarks : Dr. Debanshu Bhaduri, Dr. Vani Parmar

Session 9 : 10:25-11:15 : Precision Oncology in Breast Cancer

Session Coordinators : Dr. Kshitij Joshi & Dr. Nitin Bayas

Chairpersons : Dr. Devendra Pal

10:25-10:30

Topic 1

PS06-08 Longitudinal Neoadjuvant and Post-operative Evaluation of Circulating Tumor DNA in Early Breast Cancer using a Tumor-Informed Assay: Updated Analysis of the TRACER Cohort

Speaker : Dr. Anupkumar Rawool

10:30-10:35

Topic 2

PS09-06 Tumor infiltrating lymphocytes as a predictor of pathologic complete response to neoadjuvant therapy in HER2 positive breast cancer

Speaker : Dr. Krushna Chaudhari

Scientific Program

Day 2, Sunday 07th January, 2024

10:35–10:40

Topic 3

GS03–06 Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial

Speaker : Dr. Honey Parekh

10:40–10:45

Topic 4

The prognostic and predictive impact of circulating tumour DNA (ctDNA) dynamics in patients with metastatic Triple Negative Breast Cancer (TNBC) on olaparib based therapy: Results from Cohort E of the PlasmaMATCH trial

Speaker : Dr. Chirantan Bose

10:45–11:10

Case Based Panel Discussion

Moderator : Dr. Chirantan Bose

Panelist : Dr. Kaushal Patel, Dr. Suhas Aagre, Dr. Ashish Singh, Dr. Anupkumar Rawool, Dr. C. V. Pethe, Dr. Chetan Deshmukh, Dr. Taha Sethjiwala

11:10–11:15

Concluding Remarks : Dr. Devendra Pal

11:15–11:30 : Refreshments

Session 10 : 11:30–12:20 : HER 2 +ve Early Breast Cancer

Session Coordinators : Dr. Pritam Kalaskar & Dr. Makarand Randive

Chairpersons : Dr. Vaishali Zamre, Dr. Rajesh Saoji

Scientific Program

Day 2, Sunday 07th January, 2024

11:30–11:35

Topic 1

PS09–01 Individual patient data meta-analysis of clinical and translational biomarkers for prediction of pathological complete response (pCR) after de-escalated therapy in HER2+ breast cancer in four trials of the West German Study Group

Speaker : Dr. Manish Sharma

11:35–11:40

Topic 2

PS09–02 Event-free survival by Residual Cancer Burden (RCB) and intratumor her2 heterogeneity after neoadjuvant T-DM1 and pertuzumab for early-stage HER2-positive breast cancer

Speaker : Dr. Vivek Agarwala

11:40–11:45

Topic 3

PS13–08 Chemotherapy in geriatric patients with early stage HER2+ breast cancer: A National Cancer Database analysis.

Speaker : Dr. Mansi Khanderia

11:45–11:50

Topic 4

PS09–04 The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: sub-analysis of the APHINITY trial

Speaker : Dr. Akshay Shivchhand

11:50–12:15

Case Based Panel Discussion

Moderator : Dr. B. K. Smruti

Panelist : Dr. Prakash Devde, Dr. Pritam Kalaskar, Dr. Ashish Singh, Dr. Jayesh Gori, Dr. Neerja Gupta, Dr. Sanjay Dudhat, Dr. Bhavin Visaria, Dr. Debanshu Bhaduri

Scientific Program

Day 2, Sunday 07th January, 2024

12:15–12:20

Concluding Remarks : Dr. Vaishali Zamre, Dr. Rajesh Saoji

Session 11 : 12:20–13:20 : HER 2 +ve Metastatic Breast Cancer

Session Coordinators : Dr. Akshay Shivchhand & Dr. Ritu Dave

Chairpersons : Dr. Ashish Joshi, Dr. Mangesh Mekha

12:20–12:25

Topic 1

GS01-10 HER2CLIMB-02: Randomized, double-blind phase 3 trial of tucatinib and trastuzumab emtansine for previously treated her2-positive metastatic breast cancer

Speaker : Dr. Lovin Wilson

12:25–12:30

Topic 2

PS08-09 Impact of HER2 expression dynamics on the real-world activity of trastuzumab deruxtecan for metastatic breast cancer (RELIEVE)

Speaker : Dr. Nitin Bayas

12:30–12:35

Topic 3

PS11-05 Trastuzumab deruxtecan in patients with HER2[+] or HER2-low advanced breast cancer and pathologically confirmed leptomeningeal carcinomatosis: Results from cohort 5 of the DEBBRAH study

Speaker : Dr. Ankit Patel

12:35–12:40

Topic 4

PS11-06 Analysis of HER2 expression changes from breast primary to brain metastases including HER2 Low and impact on overall survival

Speaker : Dr. Sameeksha Dubey

Scientific Program

Day 2, Sunday 07th January, 2024

12:40–12:45

Topic 5

RF02–06 AVIATOR/TBCRC045: A randomized phase II study of vinorelbine (N) + trastuzumab (H) alone or combined with avelumab (A) +/- utomilumab (U) in patients (pts) with HER2+ metastatic breast cancer (MBC) (NCT03414658)

Speaker : Dr. Smit Sheth

12:45–13:10

Case Based Panel Discussion

Moderator : Dr. Chetan Deshmukh

Panelist : Dr. Kshitij Joshi, Dr. Pankaj Goyal, Dr. Rajat Bajaj, Dr. Krupa Shankar, Dr. Sonal Dhande, Dr. B. K. Smruti, Dr. Devendra Pal, Dr Sharada Mailankody

13:10–13:15

Concluding Remarks : Dr. Ashish Joshi, Dr. Mangesh Mekha

13:15–13:30

Conference Summary : Dr. Chirag Desai

13:30–14:15 : Conference Lunch

Official



Official Partner



6th & 7th January, 2024
Trident, BKC, Mumbai



Mays Cancer Center
UT Health MDAnderson
San Antonio Cancer Center

AAGR
American Association
for Cancer Research

